Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2008 Dec 9;26(52):6859-63. doi: 10.1016/j.vaccine.2008.09.076. Epub 2008 Oct 16.

Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation.

Author information

1
Department of Pediatrics, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan. m.shinjo@z2.keio.jp

Abstract

Immunizations using live-attenuated vaccines are not recommended for post-liver transplant children due to its theoretical risks. However, they will encounter vaccine-preventable viral diseases upon returning to real-life situations. We performed a total of 70 immunizations with four individual live-attenuated vaccines to 18 pediatric post-living donor liver transplant (LDLT) recipients who fulfilled a clinical criteria including humoral and cell-mediated immunity. The seroconversion rates at the first dose for measles (strain AIK-C), rubella (strain TO-336), varicella (strain Oka), and mumps (strains Hoshino) were 100% (15/15), 100% (15/15), 82% (9/11), and 82% (9/11), respectively. During observed period (-5 years 11 months), a few cases with waning immunity (antibodies were once produced but the levels fell over time) were seen except after rubella immunization. Clinical diseases after seroconversion or definite serious adverse effects due to immunization were not observed. Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed.

PMID:
18930096
DOI:
10.1016/j.vaccine.2008.09.076
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center